Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 100 50.
ENDURONYL FORTE vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Hydralazine: Direct vasodilation of arterioles via unknown mechanism, possibly involving nitric oxide. Hydrochlorothiazide: Thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, increasing excretion of sodium and water.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
1 tablet (hydralazine 100 mg / hydrochlorothiazide 50 mg) orally once daily. Maximum: 1 tablet daily. Titrate from lower doses of individual components.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Hydralazine: 2-8 hours (prolonged in renal impairment); Hydrochlorothiazide: 6-15 hours (increased in renal impairment)
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Hydralazine: 90% renal metabolites, 10% feces; Hydrochlorothiazide: >95% renal (tubular secretion) as unchanged drug
Category C
Category A/B
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic